NRP 2945

Drug Profile

NRP 2945

Alternative Names: NNZ 4945; NRP 2945

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Calzada; Neuren Pharmaceuticals
  • Developer CuroNZ
  • Class Neuropeptides
  • Mechanism of Action CXCR4 receptor modulators; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Epilepsy
  • Preclinical Multiple sclerosis

Most Recent Events

  • 27 Nov 2017 Adverse events data from a phase I trial in healthy volunteers released by CuroNZ (CuroNZ communication, November 2017
  • 27 Nov 2017 Pharmacodynamics data from a preclinical trial in Epilepsy released by CuroNZ (CuroNZ website, November 2017)
  • 27 Nov 2017 CuroNZ completes a phase I trial in Epilepsy (In volunteers) in Australia (CuroNZ communication, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top